Form 13-F position report

ACORDA THERAPEUTICS INC

Reported by Vivaldi Capital Management LP

ACOR 1.75 06/15/21 CUSIP 00484MAA4 Manager CIK 0001682021

Reported 0 shares, down 15,000 (100.0%) from the prior quarter.

Reported value -100.0%; share count -100.0% vs. the prior quarter.

Reduced
% of reported 13F value 0 This manager · Q2 2020
Shares 0 Quarter-end amount reported
Reported value $0 Fair value at quarter end
Consecutive quarters held 14 Through Q2 2020

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value

Quarterly position history

How this manager's reported quarter-end position changed over time.

0 quarters
Quarterly reported position history for ACORDA THERAPEUTICS INC held by Vivaldi Capital Management LP.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
This position's reported history falls outside the five-year preview window. A free account unlocks it. Unlock full history

Who else reported the position

17 managers reported ACORDA THERAPEUTICS INC for Q2 2020.

Managers reporting ACORDA THERAPEUTICS INC in Q2 2020.
Manager Activity Shares Change % of reported 13F Reported value Tenure
WELLS FARGO & COMPANY MN Unchanged 20,990,000 0 < 0.01% $17,946,000 24 qtrs
Bruce & Co Inc Unchanged 11,500,000 0 1.62% $7,475,000 4 qtrs
Davidson Kempner Capital Management LP Unchanged 0 0 0.14% $5,823,000 24 qtrs
The Goldman Sachs Group Inc Unchanged 6,080,000 0 < 0.01% $5,261,000 5 qtrs
UBS OCONNOR LLC Added 5,310,000 +1,310,000 0.1% $4,567,000 7 qtrs
CREDIT SUISSE AG Unchanged 4,205,000 0 < 0.01% $3,638,000 14 qtrs
AMERIPRISE FINANCIAL INC Unchanged 3,500,000 0 < 0.01% $3,028,000 15 qtrs
FMR LLC Unchanged 0 0 < 0.01% $2,033,000 10 qtrs
PFM Health Sciences LP Unchanged 2,000,000 0 0.09% $1,713,000 13 qtrs
PenderFund Capital Management Ltd Unchanged 1,000,000 0 0.32% $1,183,000 6 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2020
Filed
August 13, 2020
Filing type
13F-HR
Position type
Equity

Voting authority reported

No voting-authority amounts were reported for this position. Voting authority is not required for reported call options.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.